ARROWHEAD PHARMACEUTICALS IN (ARWR) Stock Income Statement
NASDAQ:ARWR - Nasdaq - US04280A1007 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-9-30) | 2023 (2023-9-30) | 2022 (2022-9-30) | 2021 (2021-9-30) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 545.21M | 3.55M | 240.70M | 243.20M | 138.30M | |||
| Minority Interest Expense | 10.71M | 10.20M | 4.00M | 400.00K | N/A | |||
| Operating Expenses | 663.76M | 604.63M | 445.70M | 421.70M | 287.30M | |||
| Research and Development | 526.43M | 478.18M | 332.00M | 281.20M | 199.00M | |||
| Selling, General, and Administrative Expenses | 116.20M | 107.86M | 101.30M | 130.10M | 80.10M | |||
| Operating Income | -118.55M | -601.08M | -205.00M | -178.50M | -149.00M | |||
| Interest Income/Expense | -32.14M | -9.63M | -3.00M | 5.00M | 6.10M | |||
| Other Income/Expense | -1.58M | -1.75M | 1.50M | 800.00K | 2.10M | |||
| Non Recurring Items | N/A | N/A | N/A | N/A | N/A | |||
| Income Before Taxes | -152.27M | -612.46M | -206.50M | -172.70M | -140.80M | |||
| Income Tax | 2.40M | -2.77M | 2.80M | 3.80M | 0.00 | |||
| Net Income | -143.97M | -599.49M | -205.30M | -176.10M | -140.80M | |||
| EBITDA | -97.43M | -582.49M | -192.50M | -168.10M | -140.70M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -1.38 | -5.00 | -1.92 | -1.67 | -1.36 | |||
| Non GAAP EPS | -1.39 | -5.01 | -1.92 | -1.68 | -1.36 | |||
| Statistics | ||||||||
| Profit Margin | -26.41% | -16882.37% | -85.29% | -72.41% | -101.81% | |||
| Operating Profit Margin | -21.74% | -16927.06% | -85.17% | -73.40% | -107.74% | |||
All data in USD